Healthcare
Elite Pharmaceuticals, Inc.(ELTP)
Live Price
Offline$0.354
-1.67% today
1Y Change
-52.59%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $380.00M
- Revenue Growth
- +48.4%
- EPS Growth
- -120.2%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Elite Pharmaceuticals, Inc. (ELTP) is a Healthcare stock with a market cap of $380.00M and listed on OTC. The stock last traded around $0.35 and down 52.6% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +48.4%, EPS growth of -120.2%, a dividend yield of 0.0%. What stands out right now is revenue +48.4%, EPS -120.2%, free cash flow +220.5% with operating margin 35.7% and ROIC 34.4%. Valuation is more restrained than many high-expectation growth names at P/E 8.7 and price/sales 2.7. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines ELTP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+48.4% vs +7.6% peer median
Operating Margin
Above sector median
+35.7% vs +19.4% peer median
P/E
Below sector median
8.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Feb 17, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +48.4% and EPS is at -120.2%, with operating margin around 35.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 17, 2026 | โ | -6.8% | -6.8% | -11.4% |
2025 Nov 14, 2025 | โ | -14.7% | -23.5% | -26.5% |
2025 Aug 14, 2025 | โ | +1.9% | +5.7% | +32.1% |
Benchmark Edge
ELTP vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ELTP
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ELTP Max Drawdown
-55.26%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ELTP and SPY.
Company Overview
Elite Pharmaceuticals, Inc.
Other OTC
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.
- Leadership
- Nasrat Hakim
- IPO Date
- Feb 24, 2000
- Employees
- 64
- Street Address
- 165 Ludlow Avenue
- Mailing
- Northvale, NJ, 07647
- Region
- Northvale, NJ, US
- Reporting Currency
- USD
- Investor Line
- 201 750 2646
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 8.7
- EV/EBITDA
- 7.9
- Price/Sales
- 2.7
- Price/Book
- 4.7
Growth
- Revenue
- +48.4%
- EPS
- -120.2%
- Free Cash Flow
- +220.5%
Profitability
- Gross Margin
- 51.1%
- Operating Margin
- 35.7%
- Net Margin
- 31.0%
- ROE
- 71.4%
- ROIC
- 34.4%
Balance Sheet
- Debt/Equity
- 0.09
- Current Ratio
- 7.34
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.